

Freya Biosciences License ApS

c/o Gorrissen Federspiel, Axeltorv 2, 1609 København V

CVR no. 41 37 20 79

Annual report 2020

(As of the establishment of the Company 19 May - 31 December 2020)

Approved at the Company's annual general meeting on 13 July 2021

Chair of the meeting:

DocuSigned by:
Peter Bisgaard
6FDA19310B0848F





Contents

Statement by the Board of Directors and the Executive Board	2
Independent auditors' report on the compilation of financial statements	3
Management's review	4
Financial statements for the period 19 May - 31 December 2020	5
Income statement	5
Balance sheet	6
Statement of changes in equity	7
Notes to the financial statements	8



Statement by the Board of Directors and the Executive Board

Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Freya Biosciences License ApS for the financial year as of the establishment of the Company 19 May - 31 December 2020.

The annual report, which has not been audited, has been prepared in accordance with the provisions of the Danish Financial Statements Act. The Board of Directors and the Executive Board have considered the criteria for omission of audit to be met.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2020 and of the results of the Company's operations for the financial year as of the establishment of the Company 19 May - 31 December 2020.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 13 July 2021
Executive Board:

DocuSigned by:

8EBBC5988C76493.....
Colleen Denise Acosta
CEO

Board of Directors:

DocuSigned by:

6FDA19310B0848F.....
Peter Finsel Bisgaard
Chair

DocuSigned by:

941BD5B3DE9246E.....
Nicholas Haft

DocuSigned by:

B0EBE736B514442.....
Mark Smith

DocuSigned by:

8EBBC5988C76493.....
Colleen Denise Acosta

DocuSigned by:

F6952847F89248C.....
Henriette Elsebeth Richter



Independent auditor's report on the compilation of financial statements

To the general management of Freya Biosciences License ApS

We have compiled the financial statements of Freya Biosciences License ApS for the financial year as of the establishment of the Company 19 May - 31 December 2020 based on the Company's bookkeeping and other information provided.

The financial statements comprise an income statement, balance sheet, statement of changes in equity and notes, including accounting policies.

We performed this compilation engagement in accordance with ISRS 4410 *Compilation Engagements*.

We have applied our expertise in accounting and financial reporting to assist you in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant ethical requirements in the Danish act on approved auditors and audit firms and FSR - Danish Auditors' code of ethics, including principles of integrity, objectivity, professional competence and due care.

The financial statements and the accuracy and completeness of the information used to compile the financial statements are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile the financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether the financial statements are prepared in accordance with the Danish Financial Statements Act.

Copenhagen, 13 July 2021
EY Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28

A handwritten signature in blue ink, appearing to read 'C. Schwenn Johansen', is written over a light blue horizontal line.

Christian Schwenn Johansen
State Authorised Public Accountant
mne33234



Management's review

Company details

Name Freya Biosciences License ApS
Address, Postal code, City c/o Gorrissen Federspiel, Axeltorv 2, 1609 København V

CVR no. 41 37 20 79
Established 19 May 2020
Registered office København
Financial year 19 May - 31 December 2020

Board of Directors Peter Finsel Bisgaard, Chair
Nicholas Haft
Mark Smith
Colleen Denise Acosta
Henriette Elsebeth Richter

Executive Board Colleen Denise Acosta, CEO

Accountant EY Godkendt Revisionspartnerselskab
Dirch Passers Allé 36, P.O. Box 250, 2000 Frederiksberg,
Denmark

Management commentary

Financial review

The income statement for 2020 shows a loss of DKK 17,500, and the balance sheet at 31 December 2020 shows equity of DKK 38,607.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.



Financial statements for the period 19 May - 31 December 2020

Income statement

Note	DKK	2020 8 months
	Gross loss	-17,500
2	Staff costs	0
	Profit/loss before tax	-17,500
	Tax for the year	0
	Profit/loss for the year	-17,500
	Recommended appropriation of profit/loss	-17,500
	Retained earnings/accumulated loss	-17,500



Financial statements for the period 19 May - 31 December 2020

Balance sheet

Note	DKK	<u>2020</u>
	ASSETS	
	Non-fixed assets	
	Receivables	
3	Other receivables	<u>56,107</u>
		<u>56,107</u>
	Total non-fixed assets	<u>56,107</u>
	TOTAL ASSETS	<u><u>56,107</u></u>
	EQUITY AND LIABILITIES	
	Equity	
4	Share capital	56,107
	Retained earnings	<u>-17,500</u>
	Total equity	<u>38,607</u>
	Liabilities other than provisions	
	Current liabilities other than provisions	
	Trade payables	<u>17,500</u>
		<u>17,500</u>
		<u>17,500</u>
	TOTAL EQUITY AND LIABILITIES	<u><u>56,107</u></u>
1	Accounting policies	
5	Collateral	



Financial statements for the period 19 May - 31 December 2020

Statement of changes in equity

DKK	<u>Share capital</u>	<u>Retained earnings</u>	<u>Total</u>
Cash payments concerning formation of enterprise	40,000	0	40,000
Capital increase	16,107	0	16,107
Transfer through appropriation of loss	0	-17,500	-17,500
Equity at 31 December 2020	<u>56,107</u>	<u>-17,500</u>	<u>38,607</u>



Financial statements for the period 19 May - 31 December 2020

Notes to the financial statements

1 Accounting policies

The annual report of Freya Biosciences License ApS for 2020 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Reporting currency

The financial statements are presented in Danish kroner (DKK).

Income statement

Gross loss

The items revenue and external expenses have been aggregated into one item in the income statement called gross loss in accordance with section 32 of the Danish Financial Statements Act.

Other external expenses

Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

The Company and its Danish group entities are jointly taxed. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).

Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.



Financial statements for the period 19 May - 31 December 2020

Notes to the financial statements

1 Accounting policies (continued)

Balance sheet

Receivables

Receivables are measured at amortised cost.

The Company has chosen IAS 39 as interpretation for impairment of financial receivables.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtors' domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.

Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.

Equity

Proposed dividends

Dividend proposed for the year is recognised as a liability once adopted at the annual general meeting (declaration date). Dividends expected to be distributed for the financial year are presented as a separate item under "Equity".

Income taxes

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

Financial statements for the period 19 May - 31 December 2020

Notes to the financial statements

1 Accounting policies (continued)

Liabilities

Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan. Financial liabilities also include the capitalised residual lease liability in respect of finance leases.

Other liabilities are measured at net realisable value.

2 Staff costs

The Company has no employees.

DKK	2020
3 Other receivables	
Client account receivable at legal advisor	40,000
Other receivables	16,107
	<u>56,107</u>

4 Share capital

The Company's share capital has remained DKK 56,107 since the establishment.

5 Collateral

The Company has not provided any security or other collateral in assets at 31 December 2020.